This inventor holds 4 USPTO granted patents and 2 published patent applications. Top assignees: Astrazeneca Ab, Astra Aktiebolag. Active years: 2001-2008.
Company Filing History:
Years Active: 2001-2008
Title: Thomas Antonsson: Innovator in Thrombin Inhibition
Introduction
Thomas Antonsson is a notable inventor based in Lindome, Sweden. He has made significant contributions to the field of thrombin inhibitors, holding a total of 4 patents. His work focuses on developing compounds that can effectively inhibit thrombin, which is crucial in treating conditions such as thrombosis.
Latest Patents
Among his latest patents, one includes "Prodrugs of thrombin inhibitors." This patent describes compounds that are useful as prodrugs of inhibitors of trypsin-like proteases, particularly thrombin. These compounds are essential in the treatment of conditions requiring thrombin inhibition, such as thrombosis, and serve as anticoagulants. Another significant patent is "Amidino derivatives and their use as thrombin inhibitors." This patent outlines compounds that act as competitive inhibitors of trypsin-like proteases, including thrombin, and are beneficial in treating thrombin-related conditions.
Career Highlights
Throughout his career, Thomas Antonsson has worked with prominent companies such as AstraZeneca AB and Astra Aktiebolag. His experience in these organizations has allowed him to develop and refine his innovative ideas in the pharmaceutical field.
Collaborations
Thomas has collaborated with notable colleagues, including David Gustafsson and Jan-Erik Nyström. These partnerships have contributed to the advancement of his research and the successful development of his patents.
Conclusion
Thomas Antonsson is a distinguished inventor whose work in thrombin inhibitors has the potential to impact medical treatments significantly. His innovative patents and collaborations highlight his commitment to advancing healthcare solutions.